Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Michael Miller
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Physiology
Living Beings
Disorders
Concepts & Ideas
Procedures
Sign-in to see full Profile
Network (preview)
18
Margot, Nicolas
6
Naeger, Lisa
6
Cheng, Andrew
6
Gibbs, Craig
6
White, Kirsten
5
Lamy, PD
5
Cherrington, Julie
5
Delaney, William
5
Mulato, Andrew
5
Wulfsohn, Michael
5
Xiong, Shelly
5
Yang, Huiling
4
Anton, KE
4
Westland, Christopher
3
Lennox, Jeffrey
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Michael Miller (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Lennox Jeffrey L; DeJesus Edwin; Lazzarin Adriano; Pollard Richard B; Madruga Jose Valdez Ramalho; Berger Daniel S; Zhao Jing; Xu Xia; Williams-Diaz Angela; Rodgers Anthony J; Barnard Richard J O; Miller Michael D; DiNubile Mark J; Nguyen Bach-Yen; Leavitt Randi; Sklar Peter;
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lancet 2009;374(9692):796-806.
-
2008: Cooper David A; Steigbigel Roy T; Gatell Jose M; Rockstroh Jurgen K; Katlama Christine; Yeni Patrick; Lazzarin Adriano; Clotet Bonaventura; Kumar Princy N; Eron Joseph E; Schechter Mauro; Markowitz Martin; Loutfy Mona R; Lennox Jeffrey L; Zhao Jing; Chen Joshua; Ryan Desmond M; Rhodes Rand R; Killar John A; Gilde Lucinda R; Strohmaier Kim M; Meibohm Anne R; Miller Michael D; Hazuda Daria J; Nessly Michael L; DiNubile Mark J; Isaacs Robin D; Teppler Hedy; Nguyen Bach-Yen;
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):355-65.
-
2008: Steigbigel Roy T; Cooper David A; Kumar Princy N; Eron Joseph E; Schechter Mauro; Markowitz Martin; Loutfy Mona R; Lennox Jeffrey L; Gatell Jose M; Rockstroh Jurgen K; Katlama Christine; Yeni Patrick; Lazzarin Adriano; Clotet Bonaventura; Zhao Jing; Chen Joshua; Ryan Desmond M; Rhodes Rand R; Killar John A; Gilde Lucinda R; Strohmaier Kim M; Meibohm Anne R; Miller Michael D; Hazuda Daria J; Nessly Michael L; DiNubile Mark J; Isaacs Robin D; Nguyen Bach-Yen; Teppler Hedy;
Raltegravir with optimized background therapy for resistant HIV-1 infection.
The New England journal of medicine 2008;359(4):339-54.
-
2007: Marchand Bruno; White Kirsten L; Ly John K; Margot Nicolas A; Wang Ruth; McDermott Martin; Miller Michael D; Götte Matthias
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
Antimicrobial agents and chemotherapy 2007;51(8):2911-9.
-
2007: Chappell Brandi J; Margot Nicolas A; Miller Michael D
Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.
AIDS (London, England) 2007;21(6):761-3.
-
2007: Miller Michael D; Margot Nicolas; McColl Damian; Cheng Andrew K
K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
AIDS (London, England) 2007;21(2):265-6.
-
2006: Margot N A; Lu B; Cheng A; Miller M D;
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
HIV medicine 2006;7(7):442-50.
-
2006: White Kirsten L; Chen James M; Feng Joy Y; Margot Nicolas A; Ly John K; Ray Adrian S; Macarthur Holly L; McDermott Martin J; Swaminathan S; Miller Michael D
The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.
Antiviral therapy 2006;11(2):155-63.
-
2005: White Kirsten L; Margot Nicolas A; Ly John K; Chen James M; Ray Adrian S; Pavelko Martina; Wang Ruth; McDermott Martin; Swaminathan S; Miller Michael D
A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.
AIDS (London, England) 2005;19(16):1751-60.
-
2005: Carruth Lucy M; Zink M Christine; Tarwater Patrick M; Miller Michael D; Li Ming; Queen Laurie A; Mankowski Joseph L; Shen Anding; Siliciano Robert F; Clements Janice E
SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy.
Journal of medical primatology 2005;34(3):109-21.
-
2005: Westland C E; Yang H; Delaney W E; Wulfsohn M; Lama N; Gibbs C S; Miller M D; Fry J; Brosgart C L; Schiff E R; Xiong S
Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.
Journal of viral hepatitis 2005;12(1):67-73.
-
2004: McColl Damian J; Margot Nicolas A; Wulfsohn Michael; Coakley Dion F; Cheng Andrew K; Miller Michael D
Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.
Journal of acquired immune deficiency syndromes (1999) 2004;37(3):1340-50.
-
2004: Delaney William E; Yang Huiling; Miller Michael D; Gibbs Craig S; Xiong Shelly
Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro.
Antimicrobial agents and chemotherapy 2004;48(10):3702-10.
-
2004: Gallant Joel E; Staszewski Schlomo; Pozniak Anton L; DeJesus Edwin; Suleiman Jamal M A H; Miller Michael D; Coakley Dion F; Lu Biao; Toole John J; Cheng Andrew K;
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA : the journal of the American Medical Association 2004;292(2):191-201.
-
2004: Tuske Steve; Sarafianos Stefan G; Clark Arthur D; Ding Jianping; Naeger Lisa K; White Kirsten L; Miller Michael D; Gibbs Craig S; Boyer Paul L; Clark Patrick; Wang Gang; Gaffney Barbara L; Jones Roger A; Jerina Donald M; Hughes Stephen H; Arnold Eddy
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.
Nature structural & molecular biology 2004;11(5):469-74.
-
2004: Dore Gregory J; Cooper David A; Pozniak Anton L; DeJesus Edwin; Zhong Lijie; Miller Michael D; Lu Biao; Cheng Andrew K;
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
The Journal of infectious diseases 2004;189(7):1185-92.
-
2004: White Kirsten L; Chen James M; Margot Nicolas A; Wrin Terri; Petropoulos Christos J; Naeger Lisa K; Swaminathan S; Miller Michael D
Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.
Antimicrobial agents and chemotherapy 2004;48(3):992-1003.
-
2004: Miller Michael D; Margot Nicolas; Lu Biao; Zhong Lijie; Chen Shan-Shan; Cheng Andrew; Wulfsohn Michael
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.
The Journal of infectious diseases 2004;189(5):837-46.
-
2004: Miller Michael D
K65R, TAMs and tenofovir.
AIDS reviews 2004;6(1):22-33.
-
2003: Delaney William E; Yang Huiling; Westland Christopher E; Das Kalyan; Arnold Eddy; Gibbs Craig S; Miller Michael D; Xiong Shelly
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
Journal of virology 2003;77(21):11833-41.
-
2003: Squires Kathleen; Pozniak Anton L; Pierone Gerald; Steinhart Corklin R; Berger Daniel; Bellos Nicholaos C; Becker Stephen L; Wulfsohn Michael; Miller Michael D; Toole John J; Coakley Dion F; Cheng Andrew;
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.
Annals of internal medicine 2003;139(5 Pt 1):313-20.
-
2003: Westland Christopher E; Yang Huiling; Delaney William E; Gibbs Craig S; Miller Michael D; Wulfsohn Michael; Fry John; Brosgart Carol L; Xiong Shelly;
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
Hepatology (Baltimore, Md.) 2003;38(1):96-103.
-
2003: Margot Nicolas A; Isaacson Erica; McGowan Ian; Cheng Andrew; Miller Michael D
Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
Journal of acquired immune deficiency syndromes (1999) 2003;33(1):15-21.
-
2002: White Kirsten L; Margot Nicolas A; Wrin Terri; Petropoulos Christos J; Miller Michael D; Naeger Lisa K
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
Antimicrobial agents and chemotherapy 2002;46(11):3437-46.
-
2002: Yang Huiling; Westland Christopher E; Delaney William E; Heathcote Elizabeth J; Ho Victoria; Fry John; Brosgart Carol; Gibbs Craig S; Miller Michael D; Xiong Shelly
Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
Hepatology (Baltimore, Md.) 2002;36(2):464-73.
-
2002: Naeger Lisa K; Margot Nicolas A; Miller Michael D
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
Antimicrobial agents and chemotherapy 2002;46(7):2179-84.
-
2002: Schooley Robert T; Ruane Peter; Myers Robert A; Beall Gildon; Lampiris Harry; Berger Daniel; Chen Shan-Shan; Miller Michael D; Isaacson Erica; Cheng Andrew K;
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.
AIDS (London, England) 2002;16(9):1257-63.
-
2002: Margot Nicolas A; Isaacson Erica; McGowan Ian; Cheng Andrew K; Schooley Robert T; Miller Michael D
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
AIDS (London, England) 2002;16(9):1227-35.
-
2001: Miller M D; Margot N A; Lamy P D; Fuller M D; Anton K E; Mulato A S; Cherrington J M
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Journal of acquired immune deficiency syndromes (1999) 2001;27(5):450-8.
-
2001: Naeger L K; Margot N A; Miller M D
Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Antiviral therapy 2001;6(2):115-26.
-
2001: Naeger L K; Margot N A; Miller M D
Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine.
Nucleosides, nucleotides & nucleic acids 2001;20(4-7):635-9.
-
2001: Miller M D; Margot N A; Hertogs K; Larder B; Miller V
Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
Nucleosides, nucleotides & nucleic acids 2001;20(4-7):1025-8.
-
1999: Miller M D; Anton K E; Mulato A S; Lamy P D; Cherrington J M
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
The Journal of infectious diseases 1999;179(1):92-100.
-
1999: Wainberg M A; Miller M D; Quan Y; Salomon H; Mulato A S; Lamy P D; Margot N A; Anton K E; Cherrington J M
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Antiviral therapy 1999;4(2):87-94.
-
1998: Miller M D; Lamy P D; Fuller M D; Mulato A S; Margot N A; Cihlar T; Cherrington J M
Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.
Molecular pharmacology 1998;54(2):291-7.
-
1998: Mulato A S; Lamy P D; Miller M D; Li W X; Anton K E; Hellmann N S; Cherrington J M
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.
Antimicrobial agents and chemotherapy 1998;42(7):1620-8.
Sign-in to see more
